Female patient talking to doctor. There was no significant difference in event-free survival between the carboplatin-containing arms. Adding carboplatin to neoadjuvant paclitaxel significantly ...
New York, NY (August 20, 2025) – A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy everolimus to standard carboplatin ...
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors Further trials are warranted that evaluate adding a 10 mg dose of ...
A phase 2 randomized study of chemoimmunotherapy with or without eflornithine (DFMO) in relapsed/refractory neuroblastoma: A Children’s Oncology Group (COG) report. This is an ASCO Meeting Abstract ...
A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy everolimus to standard carboplatin chemotherapy extends the time before disease ...
An analysis of national data found that short-term mortality was not impacted for patients with advanced cancers during the shortage of the generic platinum chemotherapy drugs cisplatin and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results